1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Fujifilm Holdings Corporation
  6. News
  7. Summary
    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FUJIFILM : Bio CDMO and Life Sciences Business Briefing

01/05/2022 | 05:28pm EDT

Bio CDMO Div. & Life Sciences Business Div.

Business Briefing

January 6, 2022

Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties, and other factors. Accordingly, actual results may differ materially from those

projected due to various factors.

Today's Agenda

1

2

Opening & Introduction :

Organization and Mid-term Plan for Healthcare

Takatoshi Ishikawa

FUJIFILM Corporation

Director, Senior Executive Vice President, CLSO

General Manager, Bio CDMO Division

Bio CDMO Division

Takatoshi Ishikawa

FUJIFILM Corporation

Director, Senior Executive Vice President, CLSO

General Manager, Bio CDMO Division

Life Sciences Business Division

3 Yutaka Yamaguchi

FUJIFILM Corporation

General Manager, Life Sciences Business Division

2

Healthcare / Life Sciences : New Organization (Effective on April 1, 2021)

  • Redefine "Healthcare" as two business groups ; "Medical Systems" and "Life Sciences".
  • Reorganize and strengthen Life Sciences businesses from a customer perspective, to prioritize Bio CDMO and drug development support businesses.
  • Become a leader within the life science industry, by offering value of end-to-end solutions as a company strongly supporting the creation of cutting-edge medicine.

Previously (March 31, 2021)

Currently (April 1, 2021)

Healthcare

Medical Systems Business Div.

Bio CDMO Div.

Regenerative Medicine Div. (Cell / Cell culture media)

Pharmaceutical Products Div.

Life Science Products Div. Cosmetics / Supplements

Healthcare

Medical Systems

Medical Systems Business Div.

* Page5-

Life Sciences

Bio CDMO Div.

CLSO

* Page28-

Life Science Business Div.

Life Sciences

(Cell/Cell culture media/Reagent)

Strategy

Headquarters

Pharmaceutical Products Div.

Consumer Healthcare Business Div.

Cosmetics / Supplements

3

Healthcare : Revenue Target for FY30

Healthcare will grow to ¥1.75 trillion in FY30.

¥1.75 trillion

(16.1B*)

Healthcare

FY30

FY21-30

Revenue

CAGR%

¥0.79 trillion (7.3B*)

FY21

*109 yen / USD

¥0.86

trillion

(7.9B*)

FY23

FY30

Medical Systems

¥1.00T

8%

(9.2B*)

¥0.50T

Bio CDMO

16%

(4.6B*)

¥0.25T

Life Sciences *

8%

(2.3B*)

* The total of 3 Business Divisions ;

Life Sciences, Pharmaceutical, & Consumer Healthcare.

Healthcare will represent 50% of total revenue in FY30.

50

32

32

FY23

FY30

FY21

¥3.50 trillion

¥2.70 trillion

¥2.51 trillion

($32.1B*)

($23.0B*)

($24.8B*)

4

Bio CDMO Division

FUJIFILM Corporation

Director, Senior Executive Vice President, CLSO

General Manager, Bio CDMO Division

Takatoshi Ishikawa

January 6, 2022

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Fujifilm Holdings Corporation published this content on 05 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 January 2022 22:27:05 UTC.


ę Publicnow 2022
All news about FUJIFILM HOLDINGS CORPORATION
10:17aFujifilm Provides Education Advancement Opportunities for Gastroenterologists and Endos..
AQ
05/17Fujifilm Showcases New Endoscopy Innovations for the Detection, Diagnosis, and Treatmen..
AQ
05/16RAYUS Radiology Partners with Fujifilm and selects Synapse« Enterprise Information Syst..
AQ
05/16RAYUS Radiology Partners with Fujifilm and Selects Synapse« Enterprise Information Syst..
CI
05/16FUJIFILM VisualSonics Launches the New Multi-modal Vevo F2 Imaging Platform for Preclin..
AQ
05/11Fujifilm's Attributable Net Income Grows 16.5% in FY22
MT
05/02Fujifilm Selected as Platinum Partner of the National Rural Health Association
AQ
04/27Fujifilm Awarded Pacific Air Force/Navy Order from the U.S. Department of Defense and D..
AQ
04/27Fujifilm Awarded Pacific Air Force/Navy Order from the U.S. Department of Defense and D..
CI
04/26FUJIFILM Diosynth Biotechnologies Breaks Ground on Expansion of its BioProcess Innovat..
AQ
More news
Financials
Sales 2022 2 514 B 19 613 M 19 613 M
Net income 2022 187 B 1 456 M 1 456 M
Net Debt 2022 136 B 1 065 M 1 065 M
P/E ratio 2022 15,3x
Yield 2022 1,55%
Capitalization 2 855 B 22 272 M 22 272 M
EV / Sales 2022 1,19x
EV / Sales 2023 1,09x
Nbr of Employees 73 275
Free-Float 74,1%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
Fujifilm Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 7 124,00 JPY
Average target price 9 876,92 JPY
Spread / Average Target 38,6%
EPS Revisions
Managers and Directors
Teiichi Goto President, CEO & Representative Director
Kenji Sukeno Chairman
Takashi Iwasaki Director & Chief Technology Officer
Kunitaro Kitamura Independent Outside Director
Tatsuo Kawada Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
FUJIFILM HOLDINGS CORPORATION-18.11%21 634
ABBOTT LABORATORIES-19.89%200 553
MEDTRONIC PLC0.12%142 552
BECTON, DICKINSON AND COMPANY2.17%73 051
BAXTER INTERNATIONAL INC.-15.98%37 432
HOYA CORPORATION-26.45%35 518